As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls.  Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading ->
Amidst the battle against a new infectious threat, the fight against tuberculosis, one of humankind’s oldest recorded infectious diseases, is also progressing. Pretomanid – only the second TB drug to hit the market in over two decades – received conditional marketing approval Monday from the European Commission as part of a new, three-drug treatment regimen […] Continue reading ->
The United Nations Interagency Coordination Group (IACG) is seeking candidates for a  “One Health Global Leaders Group” that will be established to fight the growing threat of antimicrobial resistance (AMR).  Individuals from civil society and the private sector  are invited to submit an application to serve in the Global Leaders Group by 31 August 2020. […] Continue reading ->
Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading ->